Lychee Seed Extract Targets Proliferation, Differentiation, and Cell Cycle Proteins to Suppress Human Colorectal...

Area of Science:

• Oncology
• Pharmacology
• Natural Products Chemistry

Background:

• Colorectal cancer (CRC) is a major global health concern.
• Natural products are being investigated for their multi-targeted anti-cancer properties.
• Litchi chinensis seed extract (LCSE) demonstrates in vitro anti-cancer activity, but in vivo efficacy is largely unexplored.

Purpose of the Study:

• To evaluate the in vivo anti-tumor effects of LCSE in colorectal cancer xenograft models.
• To investigate the phytochemical composition of LCSE.
• To assess the impact of LCSE on tumor growth, proliferation, and key protein expression.

Main Methods:

• Phytochemical analysis of LCSE using colorimetric assays and HPLC.
• Administration of LCSE to nude mice with HT-29 or SW480 xenografts.
• Measurement of tumor volume and analysis of protein expression (EGFR, p21, p53, Ki-67, Bax) via immunohistochemistry.

Main Results:

• LCSE contains significant amounts of phenolics and flavonoids, with gallic acid as a primary component.
• LCSE significantly inhibited tumor growth in HT-29 xenografts and dose-dependently reduced EGFR, p21, p53, and proliferation markers.
• In SW480 xenografts, inhibition was observed at higher doses, with minimal impact on p53 and no change in Bax, suggesting a non-apoptotic mechanism. No toxicity was noted.

Conclusions:

• LCSE exhibits dose-dependent anti-tumor activity in CRC xenografts, primarily by suppressing proliferation and modulating regulatory proteins.
• The mechanism appears to involve pathways other than apoptosis.
• LCSE is a safe, multi-target botanical agent with potential for CRC intervention, warranting further research.